Drug Price War: Is the US Sacrificing Future Cures for Today's Savings?

OTTAWA, Ontario – January 29, 2026 – A stark warning from a Canadian think tank is intensifying the high-stakes debate over drug pricing in the United States. The Montreal Economic Institute (MEI) released an economic note this morning cautioning that American price-control measures, such as the Most-Favored-Nation (MFN) policy, could severely limit patient access to new, life-saving medicines, echoing a troubling trend already observed in Canada.

The American Push for Lower Prices

The push to rein in prescription drug costs has become a central, bipartisan issue in American politics. The latest salvo is the "Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients" executive order, signed last May. This policy directs federal agencies to develop strategies ensuring the U.S. does not pay more for prescription drugs than other developed nations. The MFN target price is set as the lowest price for a drug in a comparable high-income country, a move proponents claim will combat the "corporate greed" that forces Americans to subsidize pharmaceutical innovation for the rest of the world.

This MFN initiative is distinct from, yet philosophically aligned with, the Inflation Reduction Act (IRA) of 2022. The IRA empowers Medicare to directly negotiate prices for a select list of high-cost drugs, with the first negotiated prices set to take effect this year. While the MFN policy relies more on voluntary agreements and tariff threats for enforcement, the IRA establishes a legally binding framework with significant penalties for non-compliance.

Together, these policies represent the most aggressive effort in decades to control drug expenditures in the U.S. Advocacy groups like AARP have championed these moves, highlighting surveys showing overwhelming public support for lower drug costs. They argue that high prices force seniors and other vulnerable patients to choose between medications and other basic necessities.

A Cautionary Tale from the North?

However, the MEI report argues that this focus on price comes with a perilous trade-off. “What’s worse than expensive medication is no medication at all,” explains Emmanuelle B. Faubert, an economist at the MEI. The think tank points to Canada's own long-standing price control system as a case study for the potential negative consequences.

Since 1987, Canada's Patented Medicine Prices Review Board (PMPRB) has set price ceilings for new medications by comparing them to a basket of other countries. In 2022, the PMPRB implemented a significant change, removing the high-price markets of the United States and Switzerland from its list of comparable countries and adding several with lower prices. According to the MEI, this applied severe downward pressure on the regulated launch prices of new drugs.

The result, the report claims, has been a chilling effect on the Canadian market's attractiveness for pharmaceutical companies. The data cited is stark: between 2018 and 2021, a period of uncertainty as these changes were debated, the proportion of new drugs with major therapeutic benefits launched in Canada within two years of their global debut plummeted from 46 percent to just 31 percent.

“Pharmaceutical research is not cheap, and neither are the efforts to ramp up production of new products,” Faubert adds. “The lower the regulated launch price is, the further down the line a market is pushed when it comes to accessing new medication.” This suggests that as U.S. prices are forced down toward international benchmarks, American patients could face similar delays for the next generation of innovative treatments.

The Industry's Dilemma: Innovation vs. Regulation

The pharmaceutical industry has reacted to these pricing pressures with alarm. Major industry groups like PhRMA have fiercely opposed the IRA's negotiation provisions, filing numerous lawsuits—most unsuccessful to date—challenging the law's constitutionality. They argue that government price setting will decimate the innovation ecosystem that produces new cures.

A key industry concern is the IRA's so-called "pill penalty," which allows for earlier price negotiations for small-molecule drugs (typically pills) compared to large-molecule biologics (often injectables). PhRMA claims this creates a powerful disincentive for research into pills, which are often more convenient for patients, and reports a steep decline in early-stage funding for small-molecule development since the law's passage.

The response from individual companies has been complex. While publicly fighting the IRA, several major firms, including Eli Lilly, Merck, and Novartis, have entered into voluntary MFN pricing agreements with the government for certain products. Critics, however, note that some of these same companies have simultaneously raised prices on other drugs, raising questions about the overall effectiveness of these non-binding deals. Ultimately, industry analysts warn that sustained revenue reductions from price controls will inevitably lead to cuts in R&D budgets, which can average nearly $900 million per successful new drug when accounting for failures. Companies may be forced to prioritize blockbuster drugs over treatments for rare diseases and delay or cancel launches in markets with stringent price controls.

Beyond the Sticker Price: The Hidden Value of New Drugs

The MEI report concludes by challenging policymakers to look beyond the immediate sticker price of a new drug and consider its broader economic value. The think tank cites Canadian research estimating that every dollar spent on new and generic medications can save between $1.05 and $1.50 in other healthcare costs, such as expensive hospital stays and invasive surgeries.

“To focus solely on the price of a new drug without considering its benefits is to miss the forest for the trees,” Faubert points out. This perspective argues that innovative medicines are not just another line item in the healthcare budget; they are investments that can generate significant returns through improved public health, increased productivity, and long-term savings for the entire system.

As the U.S. navigates this new era of drug price regulation, it stands at a critical crossroads. The path toward affordability is politically popular and addresses a genuine crisis for millions of Americans. Yet, as the Canadian experience suggests, that path may be littered with unintended consequences, potentially slowing the pace of medical discovery and delaying access to the very cures patients are waiting for. The challenge for policymakers will be to find a balance that makes existing medicines affordable without mortgaging the future of pharmaceutical innovation.